RIVAROXABAN TARO 10 MG

国家: 以色列

语言: 英文

来源: Ministry of Health

有效成分:

RIVAROXABAN

可用日期:

TARO PHARMACEUTICAL INDUSTRIES LTD

ATC代码:

B01AX06

药物剂型:

FILM COATED TABLETS

组成:

RIVAROXABAN 10 MG

给药途径:

PER OS

处方类型:

Required

厂商:

TARO PHARMACEUTICAL INDUSTRIES LTD

治疗领域:

RIVAROXABAN

疗效迹象:

* Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.* Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), in adults (following completion of at least 6 months therapy for DVT or PE).

授权日期:

2019-08-06

资料单张

_Page 1 of 8 _
Patient leaflet in accordance with the Pharmacists’ Regulations
(Preparations) -
1986
This medicine is dispensed with a doctor's prescription only
Rivaroxaban Taro 10 mg
Film-coated tablets
Active ingredient
Each tablet contains:
rivaroxaban 10 mg
Inactive ingredients and allergens in the medicine: see section 2
under ‘Important
information about some of this medicine’s ingredients’, and
section 6 ‘Additional
information'.
Read the entire leaflet carefully before you start using this
medicine. This leaflet
contains concise information about this medicine. If you have any
further questions,
consult your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass
it on to others. It
may harm them, even if it seems to you that their illness is similar
to yours.
In addition to the leaflet, Rivaroxaban Taro also has a patient safety
information
card. This card contains important safety information that you need to
know and that
you should follow before you start and during treatment with
Rivaroxaban Taro.
Carefully read the patient safety information card and patient
information leaflet
before using this medicine.
Keep the card and the leaflet in case you need to read it again.
1.
What is this medicine intended for?
Rivaroxaban Taro 10 mg is intended for:
•
Prevention of the development of blood clots in the veins in adults
after an elective
hip or knee replacement operation.
•
Prevention of re-ocurrence of blood clots in leg veins (deep vein
thrombosis, DVT)
and in the blood vessels of the lungs (pulmonary embolism, PE), after
completing
6 months of treatment for deep vein thrombosis or previous pulmonary
embolism.
Therapeutic
group:
rivaroxaban
belongs
to
a
group
of
medicines
called
antithrombotic agents and works by blocking a blood clotting factor
(factor Xa) and
thus reducing the tendency of the blood to form clots.
2.
Before using this medicine
Do not use this medicine if:
_Page 2 of 8 _
•
you are sensitive (allergic) to rivaroxaban or to any of the o